U.S. FDA approves second Alzheimer’s drug that can modestly slow disease

U.S. officials have approved another Alzheimer’s drug that can modestly slow the disease, providing a new option for patients in the early stages of the incurable, memory-destroying ailment.

Physicians who treat Alzheimer’s say the approval is an important step after decades of failed experimental treatments. The new drug’s approval was expected after an outside panel of FDA advisers unanimously voted in favour of its benefits at a public meeting last month. That endorsement came despite several questions from FDA reviewers about how Lilly studied the drug, including allowing patients to discontinue treatment after their plaque reached very low levels.

Kisunla is infused once a month compared to Leqembi’s twice-a-month regimen, which could make things easier for caregivers who bring their loved ones to a hospital or clinic for treatment.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA panel reviews psychedelic drug MDMA for the first timeThe treatment, a capsule form of MDMA, is intended to be administered to patients in combination with talk therapy sessions by a licensed mental health provider
Source: globeandmail - 🏆 5. / 92 Read more »

Bid To Approve MDMA As PTSD Treatment Overwhelmingly Rejected By FDA AdvisorsThe decision could prove a major setback for advocates who have pushed for the therapeutic use of certain banned substances.
Source: HuffPostCanada - 🏆 61. / 53 Read more »

FDA advisors oppose MDMA treatment for PTSDPharmaceutical companies focused on psychedelics are under pressure after a Food and Drug Administration (FDA) panel voted against adopting MDMA treatment...
Source: YahooFinanceCA - 🏆 47. / 63 Read more »